SCM
DNTH icon

SCS Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

SCS Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$787K Hold
9,375
– – 0.01% 305
2025
Q4 		$386K Hold
9,375
– – ﹤0.01% 401
2025
Q3 		$369K Buy
+9,375
New +$240K ﹤0.01% 423

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCS Capital Management's DNTH Position: Q1 2026 in Review

SCS Capital Management held its Dianthus Therapeutics (DNTH) position steady in Q1 2026 at 9,375 shares worth $787K. The position accounts for 0.01% of the portfolio, ranked #305.

SCS Capital Management first reported a position in DNTH in Q3 2025 and has held it in 3 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • SCS Capital Management held 9,375 shares of Dianthus Therapeutics worth $787K as of Q1 2026.
  • SCS Capital Management left its Dianthus Therapeutics share count unchanged in Q1 2026.
  • Dianthus Therapeutics made up 0.01% of SCS Capital Management's portfolio in Q1 2026, its #305 holding.
  • SCS Capital Management first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on SCS Capital Management's 13F filing for Q1 2026, filed 11 May 2026.